Acute kidney injury (AKI) is a common clinical syndrome directly related to patient short-term and long-term morbidity and mortality. Over the last decade, the occurrence rate of AKI has been increasing, and there has also been a growing epidemic of chronic kidney diseases (CKD) and end-stage kidney disease (ESRD) linked to severe and repeated episodes of AKIs. The detection and management of AKI are currently far from satisfactory. A large proportion of AKI patients, especially those with preexisting CKD, are at an increased risk of non-resolving AKI and progressing to CKD and ESRD. Proposed pathological processes that contribute to the transition of AKI to CKD and ESRD include severity and frequency of kidney injury, alterations of tubular cell phenotype with cells predominantly in the G2/M phase, interstitial fibrosis and microvascular rarification related to loss of endothelial-pericyte interactions and pericyte dedifferentiation. Innate immune responses, especially dendritic cell responses related to inadequate adenosine receptor (2a)-mediated signals, autophagic insufficiency and renin-angiotensin system activation have also been implicated in the progression of AKI and transitions from AKI to CKD and ESRD. Although promising advances have been made in understanding the pathophysiology of AKI and AKI consequences, much more work needs to be done in developing biomarkers for detecting early kidney injury, prognosticating kidney disease progression and developing strategies to effectively treat AKI and to minimize AKI progression to CKD and ESRD.

Keywords:
Biomarkers, Differential diagnosis, Chronic kidney diseases, End-stage renal failure, Prognosis, Acute kidney injury
1.
Ali T, Khan I, Simpson W, et al: Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007;18:1292-1298.
2.
Singbartl K, Kellum JA: AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012;81:819-825.
3.
Leung KC, Tonelli M, James MT: Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol 2013;9:77-85.
4.
Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH: Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med 2014;189:1075-1081.
5.
Hsu CY, Chertow GM, McCulloch CE, Fan D, Ordonez JD, Go AS: Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol 2009;4:891-898.
6.
Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK: Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 2010;298:F1078-F1094.
7.
Ishani A, Xue JL, Himmelfarb J, et al: Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009;20:223-228.
8.
Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR: Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:961-973.
9.
Perazella MA, Coca SG, Kanbay M, Brewster UC, Parikh CR: Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2008;3:1615-1619.
10.
Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR: Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2010;5:402-408.
11.
Carvounis CP, Nisar S, Guro-Razuman S: Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 2002;62:2223-2229.
12.
Pepin MN, Bouchard J, Legault L, Ethier J: Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment. Am J Kidney Dis 2007;50:566-573.
13.
Bagshaw SM, Bennett M, Devarajan P, Bellomo R: Urine biochemistry in septic and non-septic acute kidney injury: a prospective observational study. J Crit Care 2013;28:371-378.
14.
Darmon M, Vincent F, Dellamonica J, et al: Diagnostic performance of fractional excretion of urea in the evaluation of critically ill patients with acute kidney injury: a multicenter cohort study. Crit Care 2011;15:R178.
15.
Langenberg C, Wan L, Bagshaw SM, Egi M, May CN, Bellomo R: Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant 2006;21:3389-3397.
16.
Bagshaw SM, Haase M, Haase-Fielitz A, Bennett M, Devarajan P, Bellomo R: A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. Nephrol Dial Transplant 2012;27:582-588.
17.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
18.
Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
19.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138.
20.
Alge JL, Arthur JM: Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol 2015;10:147-155.
21.
Humphreys BD, Xu F, Sabbisetti V, et al: Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013;123:4023-4035.
22.
Bolignano D, Lacquaniti A, Coppolino G, et al: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337-344.
23.
Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N: The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 2005;579:773-777.
24.
Paragas N, Qiu A, Zhang Q, et al: The NGAL reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011;17:216-222.
25.
Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10:1033-1043.
26.
Flo TH, Smith KD, Sato S, et al: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917-921.
27.
Mishra J, Mori K, Ma Q, et al: Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073-3082.
28.
Mori K, Lee HT, Rapoport D, et al: Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-621.
29.
Ko GJ, Grigoryev DN, Linfert D, et al: Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition. Am J Physiol Renal Physiol 2010;298:F1472-F1483.
30.
Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M: Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 2008;31:274-279.
31.
Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY: Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009;36:45-51.
32.
Susantitaphong P, Siribamrungwong M, Doi K, Noiri E, Terrin N, Jaber BL: Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am J Kidney Dis 2013;61:430-439.
33.
Kamijo A, Sugaya T, Hikawa A, et al: Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006;284:175-182.
34.
Yamamoto T, Noiri E, Ono Y, et al: Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007;18:2894-2902.
35.
Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD: Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000;278:F667-F675.
36.
Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL: Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004;43:405-414.
37.
Anders HJ, Muruve DA: The inflammasomes in kidney disease. J Am Soc Nephrol 2011;22:1007-1018.
38.
Iyer SS, Pulskens WP, Sadler JJ, et al: Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 2009;106:20388-20393.
39.
Wu H, Craft ML, Wang P, et al: IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol 2008;19:2331-2341.
40.
Homsi E, Janino P, de Faria JB: Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int 2006;69:1385-1392.
41.
Yano T, Nozaki Y, Kinoshita K, et al: The pathological role of IL-18Rα in renal ischemia/reperfusion injury. Lab Invest 2015;95:78-91.
42.
Witzgall R, Brown D, Schwarz C, Bonventre JV: Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994;93:2175-2188.
43.
Price PM, Safirstein RL, Megyesi J: The cell cycle and acute kidney injury. Kidney Int 2009;76:604-613.
44.
Sharfuddin AA, Molitoris BA: Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 2011;7:189-200.
45.
Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV: Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535-543, 531p following 143.
46.
Kashani K, Al-Khafaji A, Ardiles T, et al: Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013;17:R25.
47.
Wetz AJ, Richardt EM, Wand S, et al: Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery? Crit Care 2015;19:3.
48.
Yamashita T, Doi K, Hamasaki Y, et al: Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. Crit Care 2014;18:716.
49.
Hoste EA, McCullough PA, Kashani K, et al: Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transplant 2014;29:2054-2061.
50.
Bihorac A, Chawla LS, Shaw AD, et al: Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014;189:932-939.
51.
Meersch M, Schmidt C, Van Aken H, et al: Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One 2014;9:e93460.
52.
Yang L, Humphreys BD, Bonventre JV: Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol 2011;174:149-155.
53.
Langenberg C, Bagshaw SM, May CN, Bellomo R: The histopathology of septic acute kidney injury: a systematic review. Crit Care 2008;12:R38.
54.
Canaud G, Bonventre JV: Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant 2015;30:575-583.
55.
Grgic I, Campanholle G, Bijol V, et al: Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012;82:172-183.
56.
Matsui K, Kamijo-Ikemori A, Hara M, et al: Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol 2011;15:220-225.
57.
Cianciolo Cosentino C, Skrypnyk NI, Brilli LL, et al: Histone deacetylase inhibitor enhances recovery after AKI. J Am Soc Nephrol 2013;24:943-953.
58.
Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY: Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010;21:31-41.
59.
Humphreys BD, Lin SL, Kobayashi A, et al: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85-97.
60.
Eardley KS, Kubal C, Zehnder D, et al: The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008;74:495-504.
61.
Eitner F, Bucher E, van Roeyen C, et al: PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008;19:281-289.
62.
Au P, Tam J, Duda DG, et al: Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo. Am J Pathol 2009;175:294-302.
63.
Lin SL, Chang FC, Schrimpf C, et al: Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011;178:911-923.
64.
Castano AP, Lin SL, Surowy T, et al: Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009;1:5ra13.
65.
Huen SC, Cantley LG: Macrophage-mediated injury and repair after ischemic kidney injury. Pediatr Nephrol 2015;30:199-209.
66.
Akcay A, Nguyen Q, Edelstein CL: Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009;2009:137072.
67.
Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011;121:4210-4221.
68.
Awad AS, Rouse M, Huang L, et al: Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009;75:689-698.
69.
Lerolle N, Nochy D, Guerot E, et al: Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med 2010;36:471-478.
70.
Kinsey GR, Sharma R, Okusa MD: Regulatory T cells in AKI. J Am Soc Nephrol 2013;24:1720-1726.
71.
Kinsey GR, Huang L, Jaworska K, et al: Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 2012;23:1528-1537.
72.
Gigliotti JC, Huang L, Ye H, et al: Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013;24:1451-1460.
73.
Bajwa A, Huang L, Kurmaeva E, et al: Sphingosine 1-phosphate receptor 3-deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury. J Am Soc Nephrol 2015;pii:ASN.2015010095.
74.
Pike F, Murugan R, Keener C, et al: Biomarker enhanced risk prediction for adverse outcomes in critically ill patients receiving RRT. Clin J Am Soc Nephrol 2015;10:1332-1339.
75.
Ding Y, Choi ME: Regulation of autophagy by TGF-β: emerging role in kidney fibrosis. Semin Nephrol 2014;34:62-71.
76.
Livingston MJ, Dong Z: Autophagy in acute kidney injury. Semin Nephrol 2014;34:17-26.
77.
Kim SI, Na HJ, Ding Y, Wang Z, Lee SJ, Choi ME: Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1. J Biol Chem 2012;287:11677-11688.
78.
Argiles A, Siwy J, Duranton F, et al: CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013;8:e62837.
79.
Schanstra JP, Zurbig P, Alkhalaf A, et al: Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol 2015;26:1999-2010.
80.
Najbauer J, Johnson BA, Young AL, Aswad DW: Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J Biol Chem 1993;268:10501-10509.
81.
Tang J, Frankel A, Cook RJ, et al: PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 2000;275:7723-7730.
82.
Ogawa T, Kimoto M, Sasaoka K: Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987;148:671-677.
83.
Nakayama Y, Ueda S, Yamagishi S, et al: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int 2014;85:570-578.
84.
Sharma M, Zhou Z, Miura H, et al: ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide. Am J Physiol Renal Physiol 2009;296:F1386-F1395.
85.
Fliser D, Kronenberg F, Kielstein JT, et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
86.
Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005;16:2449-2455.
87.
Hanai K, Babazono T, Nyumura I, et al: Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009;24:1884-1888.
88.
Kielstein JT, Boger RH, Bode-Boger SM, et al: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-176.
89.
Alge JL, Karakala N, Neely BA, et al: Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol 2013;8:184-193.
90.
Alge JL, Karakala N, Neely BA, Janech MG, Velez JC, Arthur JM; SAKInet Investigators: Urinary angiotensinogen predicts adverse outcomes among acute kidney injury patients in the intensive care unit. Crit Care 2013;17:R69.
91.
Alge JL, Karakala N, Neely BA, et al: Association of elevated urinary concentration of renin-angiotensin system components and severe AKI. Clin J Am Soc Nephrol 2013;8:2043-2052.
92.
Barrera-Chimal J, Perez-Villalva R, Rodriguez-Romo R, et al: Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 2013;83:93-103.
93.
Yamamoto T, Nakagawa T, Suzuki H, et al: Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007;18:1558-1565.
94.
Kobori H, Ohashi N, Katsurada A, et al: Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008;2:349-354.
95.
Kobori H, Urushihara M: Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflugers Arch 2013;465:3-12.
96.
Allred AJ, Chappell MC, Ferrario CM, Diz DI: Differential actions of renal ischemic injury on the intrarenal angiotensin system. Am J Physiol Renal Physiol 2000;279:F636-F645.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.